Skip to main content

Clinical Trials Using Encorafenib

Review the clinical trials studying encorafenib on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-13 of 13

Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab plus Encorafenib, for Colorectal Cancer
Status: Active
Location: 12 locations
A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors
Status: Active
Location: 10 locations
Early Identification and Treatment of Occult Metastatic Disease in Stage III Colon Cancer
Status: Active
Location: 3 locations
Nilotinib in Combination with Dabrafenib and Trametinib or Encorafenib and Binimetinib for the Treatment of BRAF V600 Mutant Metastatic or Unresectable Melanoma
Status: Active
Location: 3 locations
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
Status: Active
Location: 3 locations
Defactinib and Avutometinib with or without Encorafenib for the Treatment of Patients with Brain Metastases from Cutaneous Melanoma
Status: Active
Location: 2 locations
Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Hydroxychloroquine in Combination with Encorafenib and Cetuximab or Panitumumab in Treating Patients with Stage IV BRAF-Mutated Colorectal Cancer
Status: Active
Location: Northwestern University, Chicago, Illinois
Ulixertinib and Cetuximab or Ulixertinib, Cetuximab, and Encorafenib for the Treatment of Unresectable or Metastatic Colorectal Cancer in Patients Who Have Received EGFR or BRAF-Directed Therapy
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Adjuvant Therapy Based on Pathologic Response after Neoadjuvant Encorafenib and Binimetinib for the Treatment of Stage IIIB-IV Melanoma
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Nivolumab with Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients with BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Encorafenib, Cetuximab, and Nivolumab in Treating Patients with Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas